SCM secures £1m of funding

As part of the UK Regional Growth Fund

Dianne Sharp, MD at SCM Pharma, says the company is investing £6m in a new commercial manufacturing facility

UK-based contract development and manufacturing organisation (CDMO) SCM Pharma has been offered more than £1m of funding as part of the Government’s £2.4bn public and private financial support package.

SCM Pharma’s project was one of 130 across England selected for the Government's Regional Growth Fund (RGF).

Dianne Sharp, managing director at SCM Pharma, said the allocation of the RGF ‘is a major vote of confidence for what we are doing here at SCM Pharma’ and comes at a time when the company is investing almost £6m in a new commercial manufacturing facility that will help the company better meet the needs of clients that require licensed medicines in niche markets.

‘I also believe it’s a big thumbs up for the UK’s pharmaceutical manufacturing sector. The industry has faced a tough few years but this funding illustrates that specialist areas such as sterile manufacturing that we are involved with, which attracts business from across the world, are very much alive and kicking.’

SCM Pharma specialises in formulation development and the sterile production of products for clinical trial supplies along with the supply of licensed drugs in niche markets for specialist pharmaceutical companies.

The CDMO now has three sites in the UK and specialises in vial, ampoule and syringe filling, particularly with highly potent and toxic products that require aseptic processing using isolator technology.